
Tirzepatide· 15mg
GIP/GLP-1 dual agonist
Vendor VerdictScore
Our Rating — VialVerdict's internal supplier score until more customer reviews are available.
Product + vendor context
Tirzepatide from Apollo
This page covers Tirzepatide as sold by Apollo. Product-specific reviews are only counted when a reviewer selects this exact vendor/product pair. Vendor reviews, external review signals, and the vendor VerdictScore are shown separately so broad vendor reputation does not masquerade as product-specific proof.
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist, marketed under the brand name Mounjaro for type 2 diabetes and Zepbound for weight management. In clinical trials, it has produced some of the largest weight-loss results ever recorded for a non-surgical intervention.
Current catalogue snapshot: 15mg vial, $109.99 total, $7.33/mg, listed in stock. VialVerdict does not yet have a published purity value for this row; confirm the latest COA before ordering.
Frequently asked questions about Apollo Tirzepatide
Is Apollo Tirzepatide reviewed separately from vendor reviews?
What does VialVerdict know about this Tirzepatide listing?
Why show vendor reviews on a Tirzepatide product page?
Does VialVerdict earn from Apollo links?
Vendor-level reviews for Apollo
These reviews describe the vendor overall — shipping, packaging, support, and fulfilment — not necessarily this exact Tirzepatide listing.
Other vendors selling Tirzepatide
Ranked by rating, price, and listed product data.